Download PDF
Onkologische Welt 2026; 17(01): 24-26
DOI: 10.1055/a-2754-4823
Kongressnachlese

Metastasiertes nicht-kleinzelliges Lungenkarzinom - Neue therapeutische Horizonte in der Präzisionsmedizin

Authors

  • Alexander Kretzschmar

Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Das metastasierte nicht-kleinzellige Lungenkarzinom (NSCLC) stellt weiterhin eine erhebliche klinische Herausforderung dar. Die auf dem ESMO-Kongress 2025 vorgestellten Studiendaten mit innovativen Substanzen weisen auf neue therapeutische Möglichkeiten, bis hin zu einem Paradigmenwechsel beim Management molekular definierter und immunologisch komplexer NSCLC-Subgruppen.



Publication History

Article published online:
13 February 2026

© 2026. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Ohashi K. et al. Activity of zipalertinib against active central nervous system (CNS) metastases in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (Ex20ins)/other uncommon mutations. ESMO Congress 2025 Abstract 1847MO
    Search in Google Scholar
  • 2 Johnson ML. et al. Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). ESMO 2025 Oral Session 1849MO – Abstract 1849MO
    Search in Google Scholar
  • 3 Aggarwal C. et al. KEYMAKER-U01 substudy 01 A: Investigational agents + pembrolizumab (pembro) and chemotherapy (chemo) in untreated stage IV non-small-cell lung cancer (NSCLC). ESMO Congress 2025 Abstract 1852MO
    Search in Google Scholar
  • 4 Costin D. et al. TeLuRide-005: Phase 2 Study of EIK1001, a Toll-Like Receptor ⅞ (TLR7/8) Co-Agonist with Pembrolizumab (pembro) + Chemotherapy (chemo) as First-Line (1 L) Therapy in Stage 4 Non-Small Cell Lung Cancer (NSCLC). ESMO Congress 2025 Abstract 1850MO
    Search in Google Scholar
  • 5 Houda I. et al. Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥ 50 %: Open-label, phase 3, randomized trial (PAULIEN). ESMO Congress 2025 Abstract 1851MO
    Search in Google Scholar
  • 6 Le X. et al. Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. ESMO Congress 2025 Abstract LBA75
    Search in Google Scholar
  • 7 Popat S. et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1. ESMO Congress 2025 Abstract LBA74
    Search in Google Scholar